GAITHERSBURG, Maryland, July 12, 2017 /PRNewswire/ --
Avant Diagnostics, Inc. ("Avant") (OTC: AVDX), an oncology-focused Healthcare-IT company commercializing
As part of the agreement, the management teams of both companies will endeavor to build an oncology-focused personalized health optimization program to improve health outcomes for patients based upon oncology drugs' side effect profiles combined with advanced blood biomarker monitoring. Taken together, the companies believe they can establish a best-in-class personalized cancer patient management program tailored to allow physicians and patients to proactively mitigate potential negative drug side effects, as well as boost overall health.
Concurrent with this announcement, the Company is evaluating an initial Theralink® product launch in breast cancer that will focus on a specific treatment paradigm where our proprietary assay can immediately impact a large population of patients who may be prescribed ineffective treatments due to the insufficient biomarker testing methods currently available. The patient population of interest, with the additional Theralink information, would receive a different prescription therapy that is likely to lead to a well-defined improvement in outcomes based upon the published literature.
About Avant Diagnostics, Inc.
Avant is a healthcare information solutions company that specializes in biomarker tests that are being developed in the areas of oncology and neurology. Avant provides personalized medicine diagnostic testing capabilities through its TheraLink® diagnostic assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders for over 30 FDA-approved drug treatment regimens. Avant is the leading developer of phospho-proteomic technologies for measuring the activation status of key signaling pathways, with applications across several different cancer types, including breast, ovarian, colorectal and pancreatic, that are instrumental in the development of companion diagnostics for molecular-targeted therapies. Avant has used these proteomic technologies to support the drug development programs of many of the top biopharmaceutical companies in the world. More information can be found at the website for the Company's wholly-owned subsidiary Theranostics Health at http://www.theranosticshealth.com.
Avant is also developing OvaDx® for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated proteomic microarray-based test that measures the activation of the immune system markers in blood samples in response to ovarian tumor cell development.
Avant's neurology division was recently acquired from Amarantus Bioscience Holdings, Inc. (OTC: AMBS) and owns certain rights to next-generation DNA sequencing (NGS) assay for the identification of patients with autoimmune disorders, and has an exclusive license to The LymPro Test™ for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig. The Company also owns intellectual property for the proteomic-based diagnosis of Parkinson's disease (NuroPro), and other cell-cycle-related disorders.
For further information please visit http://www.Avantdiagnostics.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant's Form 10-K filed with the Securities and Exchange Commission on January 13, 2016, and other periodic reports filed with the Securities and Exchange Commission.
Investor and Media Contact: Ascendant Partners, LLC Richard Galterio 732-410-9810 firstname.lastname@example.org
SOURCE Avant Diagnostics, Inc.
Subscribe to our Free Newsletters!
Necrotizing fasciitis is a rare life threatening bacterial infection of the tissue below the skin ...
Menstruation or period is the discharge of blood and mucus called menses from the uterus via the ...
Chronic dieting is associated with eating disorders that mainly include unhealthy eating practices ...View All